West Pharmaceutical Services is well positioned for growth, backed by strong demand for high-value products, expanding GLP-1 drug programs, and regulatory-driven Annex 1 conversions, though tariff impacts, destocking in generics, and execution challenges at constrained European facilities are concerns. Shares have gained 29.9% year to date against an industry decline of 0.7%, while the S&P 500 has risen 9.7%. The company, with a market capitalization of $25.41 billion, delivered a trailing four-quarter average earnings surprise of 19.37% and expects earnings to improve 13.9% over the next five years. Its high-value product components business delivered 23% organic growth in the first quarter, with more than two-thirds of the outperformance coming from non-GLP-1 products, and management raised full-year organic growth guidance to 7-9%. Annex 1-related projects increased 66% year over year, and the company expects Annex 1 and HVP conversion to contribute approximately 200 basis points to annual revenue growth in 2026, targeting at least 6 billion units for conversion. GLP-1-related HVP component sales represented 10% of total company revenues, and the biologics business grew 26% organically in the first quarter. The Zacks Consensus Estimate for 2026 earnings is $8.60 per share, implying an 18% gain, on revenues of $3.33 billion, indicating an 8.4% increase from the prior year.
West Pharmaceutical Services IncStrong demand for high-value products and GLP-1 drug programs driving growth.
Align Technology Inc
Cardinal Health Inc
Intuitive Surgical Inc